Compositions and methods for treating psoriasis
Granted: May 2, 2017
Patent Number:
9636321
Novel isohexides and pharmaceutical compositions containing the same as well as methods of using the same in the treatment of psoriasis.
Synthesis of cyclopentaquinazolines
Granted: August 19, 2014
Patent Number:
8809526
A method of producing 6-amino-cyclopenta[g]quinazolines, in enantiomerically enriched form, is provided. In particular, the method may be applicable to the synthesis of N—{N-{4-[N-((6S)-2 -hydroxymethyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclo-penta[g]quinazolin-6-yl)-N-(prop-2 -ynyl)amino]benzoyl}-L-?-glutamyl}-D-glutamic acid (ONX-0801).
Nucleic acids and polypeptides related to a guanine exchange factor of Rho GTPase
Granted: August 9, 2011
Patent Number:
7994294
The present invention relates to all aspects of a guanine exchange factor (GEF), for example, a Rho-GEF, such as p115 Rho-GEF. A GEF modulates cell signaling pathways, both in in vitro and in vivo, by modulating the activity of a GTPase. By way of illustration, a p115 Rho-GEF, which modulates the activity of a Rho GTPase, is described. However, the present invention relates to other GEFs, especially other Rho-GEFs. The present invention particularly relates to an isolated p115 Rho-GEF…
Adenoviral vectors for treating disease
Granted: November 9, 2010
Patent Number:
7829329
Adenoviral vectors, including mutant adenoviruses, that have restriction sites in the E3 region, that facilitate its partial or total deletion, or select genes contained therein, and optionally compositions and methods for substituting heterologous gene(s) in the partially or totally deleted E3 region(s), which heterologous gene(s) being operably linked to endogenous adenoviral transcriptional control sequences will exhibit an expression pattern, both in terms of timing and degree of…
Adenovirus E1B-55K single amino acid mutants and methods of use
Granted: August 31, 2010
Patent Number:
7785887
Adenoviral mutants are described that have single amino acid mutations in the E1B-55K protein which mutations effect the p53 binding/inactivation and the late functions of the E1B-55K protein in a manner that enhances the efficacy of such viruses for treating cancer when compared to adenoviral mutants that have the E1B-55K region deleted.
Nucleic acids encoding cytosine deaminase
Granted: July 7, 2009
Patent Number:
7556955
A new cytosine deaminase gene and protein from Candida kefyr are provided. This protein has increased ability to convert the 5-fluorocytosine prodrug to its toxic form when compared against the E. coli enzyme.
Nucleic acids and polypeptides which resemble Rho and which interact with cell signalling pathways and proteins
Granted: October 28, 2008
Patent Number:
7442534
The present invention relates to an isolated full-length Chp polypeptide, a biologically-active polypeptide fragment thereof, and nucleic acids which code for it. This polypeptide has various activities in regulating cell signaling and signal transduction pathways, including, e.g., a PAK regulatory domain binding activity, a PAK kinase stimulatory activity, a JNK kinase stimulatory activity, a cytoskeletal-reorganizing activity, or a Chp-specific immunogenic activity. The invention…
Antibody that specifically binds to Cytosine deaminase
Granted: August 19, 2008
Patent Number:
7414113
A new cytosine deaminase gene and protein from Candida kefyr are provided. This protein has increased ability to convert the 5-fluorocytosine prodrug to its toxic form when compared against the E. coli enzyme.
Oncolytic adenovirus
Granted: July 8, 2008
Patent Number:
7396679
Viral vectors and methods of making such vectors are described that preferentially kill neoplastic but not normal cells, the preferred vector being an adenovirus that has the endogenous promoters in the E1A and/or E4 regions substituted with a tumor specific promoter which is preferably E2F responsive.
Pharmaceutical compositions comprising thieno[2,3-c]pyridine derivatives and use thereof
Granted: April 29, 2008
Patent Number:
7365080
The present invention provides thieno[2,3-C]pyridine derivatives, pharmaceutical compositions comprising the thieno[2,3-C]pyridine derivatives, and methods of use thereof. The compounds capable of inhibiting glycosaminoglycan (GAG) interactions with effector cell adhesion molecules (ECAM) are useful for treating diseases and disorders mediated by GAG-ECAMs interactions, particularly inflammatory and autoimmune diseases, viral diseases, cancer, and amyloid disorders.
RAF-MEK-ERK pathway inhibitors to treat cancer
Granted: December 11, 2007
Patent Number:
7307071
Materials and methods for treating certain cancers are described, preferably cancers that result from the up-regulation of the RAF-MEK-ERK pathway, and more preferably chronic myelogenous leukemia, and which cancer is preferably resistant to the inhibition of the Bcr-Abl tyrosine kinase, imatinib.
Nucleic acids and polypeptides related to a guanine exchange factor of Rho GTPase
Granted: December 12, 2006
Patent Number:
7148002
The present invention relates to all aspects of a guanine exchange factor (GEF), for example, a Rho-GEF, such as p115 Rho-GEF. A GEF modulates cell signaling pathways, both in in vitro and in vivo, by modulating the activity of a GTPase. By way of illustration, a p115 Rho-GEF, which modulates the activity of a Rho GTPase, is described. However, the present invention relates to other GEFs, especially other Rho-GEFs. The present invention particularly relates to an isolated p115 Rho-GEF…
cytosine deaminase
Granted: November 28, 2006
Patent Number:
7141404
A new cytosine deaminase gene and protein from Candida kefyr are provided. This protein has increased ability to convert the 5-fluorocytosine prodrug to its toxic form when compared against the E. coli enzyme.
Oncolytic adenovirus
Granted: July 18, 2006
Patent Number:
7078030
Viral vectors and methods of making such vectors are described that preferentially kill neoplastic but not normal cells, the preferred vector being an adenovirus that has the endogenous promoters in the E1A and/or E4 regions substituted with a tumor specific promoter which is preferably E2F responsive.
Oncolytic adenovirus
Granted: February 21, 2006
Patent Number:
7001596
Viral vectors and methods of making such vectors are described that preferentially kill neoplastic but not normal cells, the preferred vector being an adenovirus that has the endogenous promoters in the E1A and/or E4 regions substituted with a tumor specific promoter which is preferably E2F responsive.
Phosphoinositide 3-kinases
Granted: May 10, 2005
Patent Number:
6890747
The present invention relates PI3K crystals, polypeptide muteins, polypeptide fragments, antibodies thereto, nucleic acids coding for these polypeptides, methods of modifying PI3K? activity, and methods of modulating PI3K? activity. These include polypeptides and methods thereof, relating to, e.g., phospholipid binding, lipid kinase activity, modulating Ras activity in activating the PI3K?, binding of PI3K? to cell membranes, and modulating protein—protein interactions with PI3K?.
Adenovirus E1B shuttle vectors
Granted: July 20, 2004
Patent Number:
6764674
Provided are replication competent, recombinant adenovirus vectors containing mutations in the E1B region which permit the easy deletion of a gene or genes therein, and optionally the substitution therefore of a heterologous gene that substantially exhibits the temporal expression pattern of the E1b region gene(s) deleted. Such vectors have applications for the treatment of disease, and preferably for the treatment of neoplastic disease.
Nucleotide sequences that encode phosphatidylinositol-3? kinase associated proteins and uses thereof
Granted: July 13, 2004
Patent Number:
6762284
Identification, characterization and expression of nucleotides that encode phosphatidylinositol-3′kinase associated protein(s) that bind to the intermediate SH2 domain on the regulatory subunit of PI3K, p85, by the associated protein(s) C-terminal amino acids, and that exhibit a bromodomain are described, as well as methods of using such proteins for medical applications, including diagnosis and treatment cell growth disorders.
Herpes simplex virus-1 Glycoprotein C mutants for treating unwanted hyperproliferative cell growth
Granted: April 20, 2004
Patent Number:
6723316
The present invention relates to pharmaceutical compositions, kits, and methods of use thereof, comprising, a mutant human herpes simplex virus, which is cytopathic to susceptible target cells, such as neoplastic cells. Preferably, the virus does not produce a functionally active wild-type gC polypeptide coded for the UL44 gene.
Compositions and methods for identifying PKB kinase inhibitors
Granted: January 27, 2004
Patent Number:
6682920
Compositions and methods are described that are useful to assay for compouds that affect PKB kinase activity which have medical applications for the diagnosis and treatment of disease.
